Literature DB >> 18794386

Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.

Guillermo Garcia-Effron1, Dimitrios P Kontoyiannis, Russell E Lewis, David S Perlin.   

Abstract

We identified three cases of C. tropicalis strains causing breakthrough fungemia in allogeneic stem cell recipients receiving caspofungin prophylaxis and treatment. Three genetically unrelated isolates with high echinocandin MICs were identified. Each strain carried a characteristic mutation conferring an amino acid substitution within Fks1p hot spot 1.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18794386      PMCID： PMC2573122          DOI： 10.1128/AAC.00802-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

2.  Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.

Authors:  Jennifer Nielsen Kahn; Guillermo Garcia-Effron; Ming-Jo Hsu; Steven Park; Kieren A Marr; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

3.  Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.

Authors:  Sergey V Balashov; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 4.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

5.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Risk Factors for Candida tropicalis fungemia in patients with cancer.

Authors:  D P Kontoyiannis; I Vaziri; H A Hanna; M Boktour; J Thornby; R Hachem; G P Bodey; I I Raad
Journal:  Clin Infect Dis       Date:  2001-09-24       Impact factor: 9.079

7.  Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.

Authors:  Nicholas Kartsonis; John Killar; Lori Mixson; Chao-Min Hoe; Carole Sable; Kenneth Bartizal; Mary Motyl
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

9.  Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.

Authors:  Lillian S Chou; Russell E Lewis; Cindy Ippoliti; Richard E Champlin; Dimitrios P Kontoyiannis
Journal:  Pharmacotherapy       Date:  2007-12       Impact factor: 4.705

10.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

Authors:  Jo-Anne H van Burik; Voravit Ratanatharathorn; Daniel E Stepan; Carole B Miller; Jeffrey H Lipton; David H Vesole; Nancy Bunin; Donna A Wall; John W Hiemenz; Yoichi Satoi; Jeanette M Lee; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-10-27       Impact factor: 9.079
View more
  53 in total

1.  Deletion of the Candida albicans PIR32 results in increased virulence, stress response, and upregulation of cell wall chitin deposition.

Authors:  Wael Bahnan; Joseph Koussa; Samer Younes; Marybel Abi Rizk; Bassem Khalil; Sally El Sitt; Samer Hanna; Mirvat El-Sibai; Roy A Khalaf
Journal:  Mycopathologia       Date:  2012-03-06       Impact factor: 2.574

2.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

3.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

4.  Novel FKS mutations associated with echinocandin resistance in Candida species.

Authors:  Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph DiPersio; David S Perlin; Mahmoud Ghannoum; Hector Bonilla
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

5.  Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.

Authors:  A Fekkar; I Meyer; J Y Brossas; E Dannaoui; M Palous; M Uzunov; S Nguyen; V Leblond; D Mazier; A Datry
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

6.  Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.

Authors:  Rasmus Hare Jensen; Helle Krogh Johansen; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

7.  Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Authors:  Fernando César Bizerra; Cristina Jimenez-Ortigosa; Ana Carolina R Souza; Giovanni Luis Breda; Flávio Queiroz-Telles; David S Perlin; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

8.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

9.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

10.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.